Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sedana Medical ABOSTO:SEDANA -1.01%69 Altman Z-Score is 11.62 as of Aug. 02, 2026, which is 63% below its 10-year median of 31.50. GuruFocus rates OSTO:SEDANA with a GF Score™ of 69/100 and a GF Value™ of kr17.42 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 806 Medical Devices & Instruments companies, Sedana Medical AB ranks better than 85.11% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 10.4 is strong.
Sedana Medical AB has a Altman Z-Score of 11.62, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Sedana Medical AB's Altman Z-Score or its related term are showing as below:
OSTO:SEDANA'
s Altman Z-Score Range Over the Past 10 Years
Min: 1.23 Med: 31.5 Max: 127.99
Current: 10.4
During the past 11 years, Sedana Medical AB's highest Altman Z-Score was 127.99. The lowest was 1.23. And the median was 31.50.
Sedana Medical AB (OSTO:SEDANA) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Sedana Medical AB Altman Z-Score Related Terms
Sedana Medical AB Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Sedana Medical AB's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SEDANA vs ABT, SYK, MDT: Altman Z-Score Comparison
For the Medical Devices subindustry, Sedana Medical AB's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sedana Medical AB Altman Z-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sedana Medical AB's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Sedana Medical AB's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Sedana Medical AB's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.0913
+
1.4
*
-0.3626
+
3.3
*
-0.0304
+
0.6
*
19.8435
+
1.0
*
0.2085
=
11.62
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Sedana Medical AB (OSTO:SEDANA) has a Altman Z-Score of 11.62 as of Aug. 02, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Sedana Medical AB and its competitors. This is 63% below median its historical median of 31.50. Over the past decade, Sedana Medical AB's Altman Z-Score has ranged from 1.23 to 127.99. According to the industry distribution chart, Sedana Medical AB ranks #120 out of 806 companies in the Medical Devices & Instruments industry, placing it in the top 14.9%.
Is Sedana Medical AB's Altman Z-Score too high?
Sedana Medical AB's current Altman Z-Score of 11.62 is 63% below median its 10-year median of 31.50. Over the past 10 years, this metric has ranged from a low of 1.23 to a high of 127.99. The Medical Devices & Instruments industry median Altman Z-Score is 2.99. Sedana Medical AB's value of 11.62 is 288.6% above this industry median. Based on the distribution chart, Sedana Medical AB ranks #120 out of 806 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sedana Medical AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sedana Medical AB's Altman Z-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sedana Medical AB ranks #120 out of 806 companies for Altman Z-Score. This places Sedana Medical AB in the top 15% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.99. Sedana Medical AB's value of 11.62 is 288.6% above this benchmark. Historically, Sedana Medical AB's own Altman Z-Score has ranged from 1.23 to 127.99 over the past decade. While the company's 10-year median is 31.50 vs. the industry median of 2.99, Sedana Medical AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Devices & Instruments company?
The median Altman Z-Score among Medical Devices & Instruments companies is 2.99, based on 806 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sedana Medical AB's current Altman Z-Score of 11.62 is 288.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Sedana Medical AB and its competitors. For the Medical Devices & Instruments industry, the median Altman Z-Score is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sedana Medical AB's current Altman Z-Score is 11.62, which is 63% below median its own 10-year median of 31.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sedana Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Sedana Medical AB (OSTO:SEDANA) is currently considered Significantly Undervalued. The stock's GF Value™ is kr17.42, compared to a current price of kr9.80 — trading 43.7% below its estimated fair value. The current Altman Z-Score is 11.62, which is 63% below median its 10-year median of 31.50 and 288.6% above the Medical Devices & Instruments industry median of 2.99. Sedana Medical AB's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Sedana Medical AB (OSTO:SEDANA), the current Altman Z-Score is 11.62 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sedana Medical AB (OSTO:SEDANA) Overvalued in 2026?
Based on GuruFocus' analysis, Sedana Medical AB stock appears to be undervalued.
The current stock price of kr9.80 is trading 43.7% below its estimated GF Value™ of kr17.42.
GuruFocus considers Sedana Medical AB to be Significantly Undervalued.
Key valuation signals for OSTO:SEDANA:
Altman Z-Score: 11.62 (63% below median its 10-year median of 31.50)
GF Value™: kr17.42 vs. price of kr9.80 (43.7% below fair value)
Industry Position: 288.6% above the Medical Devices & Instruments median (#120 of 806)
No single metric tells the full story. See the OSTO:SEDANA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sedana Medical AB is a Sweden-based medical technology company. It is ais a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care. Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, and Spain. In other parts of Europe, as well as in Asia, Australia, Canada, and South and Central America, the company works with external distributors.
69GF Score
Get the complete analysis for OSTO:SEDANA
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SEDANA has been successfully added to your 
